Skip to main content
Erschienen in: Lung 5/2020

22.07.2020 | LUNG TRANSPLANTATION

Risk Factors for Cytomegalovirus Reactivation in Lung Transplant Recipients

verfasst von: Se Hyun Kwak, Su Hwan Lee, Moo Suk Park, Su Jin Jeong, Jin Gu Lee, Hyo Chae Paik, Young Sam Kim, Joon Chang, Song Yee Kim

Erschienen in: Lung | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We examined risk factors that may have contributed to Cytomegalovirus (CMV) reactivation among patients who underwent lung transplantation (LTx).

Methods

We reviewed medical records of patients who underwent LTx at a tertiary healthcare hospital in South Korea between January 2013 and May 2017. We excluded patients who died within the first year after LTx and those lost to follow-up. CMV reactivation was defined as the detection of CMV titers above 3000 copies/ml regardless of specific symptoms after prophylaxis cessation.

Results

Of 89 patients included, 39 (43.8%) developed CMV reactivation. Of those 39 patients, 16 (41.0%) experienced additional CMV reactivation. Multivariate analysis identified lymphocyte counts below 1.0 × 103/μl (hazard ratio [HR] 49.33, p < 0.001) and use of steroids at more than twice the standard dose (HR 8.07, p < 0.001) as risk factors for CMV reactivation. The multivariate model also identified chronic kidney disease (CKD; HR 5.19, p = 0.016) and pneumonia (HR 17.22, p = 0.013) as risk factors for repetitive CMV reactivation.

Conclusion

This study suggests that lymphopenia and high doses of steroids may be important risk factors for CMV reactivation in LTx patients. Our results also suggest that repetitive CMV reactivation may be associated with CKD and pneumonia.
Literatur
1.
Zurück zum Zitat Xue Y, Jiang L, Wan WG et al (2016) Cytomegalovirus pneumonia in patients with rheumatic diseases after immunosuppressive therapy: a single center study in China. Chin Med J (Engl) 129(3):267–273CrossRef Xue Y, Jiang L, Wan WG et al (2016) Cytomegalovirus pneumonia in patients with rheumatic diseases after immunosuppressive therapy: a single center study in China. Chin Med J (Engl) 129(3):267–273CrossRef
2.
Zurück zum Zitat Lumbreras C, Manuel O, Len O et al (2014) Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect 20(Suppl 7):19–26CrossRef Lumbreras C, Manuel O, Len O et al (2014) Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect 20(Suppl 7):19–26CrossRef
3.
Zurück zum Zitat Bando K, Paradis IL, Komatsu K et al (1995) Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 109(1):49–57; (discussion 57–49)CrossRef Bando K, Paradis IL, Komatsu K et al (1995) Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 109(1):49–57; (discussion 57–49)CrossRef
4.
Zurück zum Zitat Zamora MR, Davis RD, Leonard C (2005) Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80(2):157–163CrossRef Zamora MR, Davis RD, Leonard C (2005) Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80(2):157–163CrossRef
5.
Zurück zum Zitat Zamora MR (2004) Cytomegalovirus and lung transplantation. Am J Transplant 4(8):1219–1226CrossRef Zamora MR (2004) Cytomegalovirus and lung transplantation. Am J Transplant 4(8):1219–1226CrossRef
6.
Zurück zum Zitat Duncan SR, Paradis IL, Yousem SA et al (1992) Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 146(6):1419–1425CrossRef Duncan SR, Paradis IL, Yousem SA et al (1992) Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 146(6):1419–1425CrossRef
7.
Zurück zum Zitat Estenne M, Maurer JR, Boehler A et al (2002) Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21(3):297–310CrossRef Estenne M, Maurer JR, Boehler A et al (2002) Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21(3):297–310CrossRef
8.
Zurück zum Zitat Sharples LD, McNeil K, Stewart S et al (2002) Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 21(2):271–281CrossRef Sharples LD, McNeil K, Stewart S et al (2002) Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 21(2):271–281CrossRef
9.
Zurück zum Zitat Tamm M, Aboyoun CL, Chhajed PN et al (2004) Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 170(10):1120–1123CrossRef Tamm M, Aboyoun CL, Chhajed PN et al (2004) Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 170(10):1120–1123CrossRef
10.
Zurück zum Zitat Verleden SE, Vasilescu DM, Willems S et al (2014) The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med 189(3):292–300CrossRef Verleden SE, Vasilescu DM, Willems S et al (2014) The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med 189(3):292–300CrossRef
11.
Zurück zum Zitat Kotton CN, Kumar D, Caliendo AM et al (2018) The Third International consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102(6):900–931CrossRef Kotton CN, Kumar D, Caliendo AM et al (2018) The Third International consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102(6):900–931CrossRef
12.
Zurück zum Zitat Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96(4):333–360CrossRef Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96(4):333–360CrossRef
13.
Zurück zum Zitat Seo S, Cho Y, Park J (2009) Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. Korean J Lab Med 29(6):557–562CrossRef Seo S, Cho Y, Park J (2009) Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. Korean J Lab Med 29(6):557–562CrossRef
14.
Zurück zum Zitat Choi SR, Kim KR, Kim DS, Kang JM et al (2018) Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine 25(3):123–131CrossRef Choi SR, Kim KR, Kim DS, Kang JM et al (2018) Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine 25(3):123–131CrossRef
15.
Zurück zum Zitat Hibberd PL, Tolkoff-Rubin NE, Cosimi AB et al (1992) Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53(1):68–72CrossRef Hibberd PL, Tolkoff-Rubin NE, Cosimi AB et al (1992) Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53(1):68–72CrossRef
16.
Zurück zum Zitat Levin A, Stevens PE, Bilous RW et al (2013) Kidney Disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150CrossRef Levin A, Stevens PE, Bilous RW et al (2013) Kidney Disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150CrossRef
17.
Zurück zum Zitat Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338(24):1741–1751CrossRef Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338(24):1741–1751CrossRef
18.
Zurück zum Zitat Choi SR, Kim K-R, Kim DS et al (2018) Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine 25(3):123–131CrossRef Choi SR, Kim K-R, Kim DS et al (2018) Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine 25(3):123–131CrossRef
19.
Zurück zum Zitat Schoeppler KE, Lyu DM, Grazia TJ et al (2013) Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant 13(2):376–382CrossRef Schoeppler KE, Lyu DM, Grazia TJ et al (2013) Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant 13(2):376–382CrossRef
20.
Zurück zum Zitat Takizawa Y, Inokuma S, Tanaka Y et al (2008) Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 47(9):1373–1378CrossRef Takizawa Y, Inokuma S, Tanaka Y et al (2008) Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 47(9):1373–1378CrossRef
21.
Zurück zum Zitat Auphan N, DiDonato JA, Rosette C et al (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):286–290CrossRef Auphan N, DiDonato JA, Rosette C et al (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):286–290CrossRef
22.
Zurück zum Zitat Girndt M, Sester U, Sester M et al (1999) Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14(12):2807–2810CrossRef Girndt M, Sester U, Sester M et al (1999) Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14(12):2807–2810CrossRef
Metadaten
Titel
Risk Factors for Cytomegalovirus Reactivation in Lung Transplant Recipients
verfasst von
Se Hyun Kwak
Su Hwan Lee
Moo Suk Park
Su Jin Jeong
Jin Gu Lee
Hyo Chae Paik
Young Sam Kim
Joon Chang
Song Yee Kim
Publikationsdatum
22.07.2020
Verlag
Springer US
Erschienen in
Lung / Ausgabe 5/2020
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-020-00380-z

Weitere Artikel der Ausgabe 5/2020

Lung 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.